Tonix Pharmaceuticals (TNXP) Offers Additional Data from Phase 2b BESTFIT of Tonmya
Tweet Send to a Friend
Tonix Pharmaceuticals (NASDAQ: TNXP) presents additional results from its completed 12-week, 205-patient Phase 2b BESTFIT clinical study of Tonmya (TNX-102 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
